Alnylam now says search for research partners may extend beyond end of year.

A good IPO will consider the needs of long-time investors as well as new ones. Here is the good the bad about two IPOs.

Drug stocks climb with the broader market in morning activity, the day after the U.S. government releases eagerly-anticipated results from its "stress testing" of several of the nation's top financial institutions.

- New Results Demonstrate Robust Anti-Tumor Activity in Multiple Models, Including Extra-Hepatic Tumors -

- Update on Pipeline Includes New Pre-clinical In Vivo Data Demonstrating that ALN-TTR Blocks Pathogenic Tissue Deposition of Mutant TTR Protein by Greater than 95% -

– Research Findings Include Rational Design of Mimetic Lipoprotein Particles (MLPs), a Novel Delivery Technology, New Data Regarding Potency of RNAi-Mediated Gene Silencing, and an Update on RNA Activation Research Efforts –